Alpha Cognition Secures $35 Million in Oversubscribed Public Offering to Accelerate Neurodegenerative Disease Treatments

Alpha Cognition Inc. (NASDAQ: ACOG) has priced an oversubscribed underwritten public offering of 5.6 million common shares at $6.25 per share, generating approximately $35 million in gross proceeds before expenses. The biopharmaceutical company intends to use the net proceeds to accelerate commercialization efforts for ZUNVEYL(R) (Benzgalantamine), including expanding sales operations, enhancing marketing initiatives, and building payer coverage and reimbursement infrastructure. CEO Michael McFadden emphasized that this funding will help maximize near-term adoption while establishing a foundation for long-term growth in the neurodegenerative disease treatment market.

The company's lead product, ZUNVEYL, represents a significant advancement in Alzheimer's disease treatment as a patented new generation acetylcholinesterase inhibitor with expected minimal gastrointestinal side effects. Unlike existing treatments such as donepezil and rivastigmine, ZUNVEYL's active metabolite uniquely binds neuronal nicotinic receptors, particularly the alpha-7 subtype, which has demonstrated positive effects on cognition. This differentiation positions the treatment as a potentially superior option for patients suffering from Alzheimer's Disease, a condition affecting millions worldwide with limited effective treatment options currently available.

Beyond ZUNVEYL's immediate applications, Alpha Cognition is developing ALPHA-1062 in combination with memantine for moderate to severe Alzheimer's dementia and as an intranasal formulation specifically targeting Cognitive Impairment associated with mild Traumatic Brain Injury (mTBI). The mTBI treatment represents a particularly important development area since there are currently no approved treatment options for cognitive impairment resulting from traumatic brain injuries. The successful funding round enables the company to advance these multiple therapeutic candidates simultaneously, addressing significant unmet medical needs across different neurodegenerative conditions.

Titan Partners Group, a division of American Capital Partners, served as sole bookrunner for the offering and was granted a 30-day option to purchase up to an additional 840,000 shares to cover potential over-allotments. The oversubscribed nature of the offering indicates strong investor confidence in Alpha Cognition's pipeline and commercialization strategy. For additional information about the company's development programs and treatment approaches, visit https://www.alphacognition.com/. The funding comes at a critical time as the global population ages and the prevalence of neurodegenerative diseases continues to increase, highlighting the urgent need for innovative treatments that can improve patient outcomes and quality of life.